2021
Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study. The Lancet Regional Health - Europe 2021, 7: 100126. PMID: 34557837, PMCID: PMC8454757, DOI: 10.1016/j.lanepe.2021.100126.Peer-Reviewed Original ResearchInvasive pneumococcal diseasePneumococcal vaccine uptakeVaccine effectivenessPneumococcal vaccinationPneumococcal diseaseVaccine uptakeOlder adultsSerotype 3 invasive pneumococcal diseaseSerotype 3Indirect cohort methodOverall vaccine effectivenessRetrospective cohort studyInvestigator-initiated research grantIPD episodesCohort studyPneumococcal vaccinePolysaccharide vaccineVaccination statusPPV23Age groupsCohort methodVaccinationAdultsSerotypesVaccine
2019
Limited indirect effects of an infant pneumococcal vaccination program in an aging population
van der Linden M, Imöhl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLOS ONE 2019, 14: e0220453. PMID: 31369597, PMCID: PMC6675109, DOI: 10.1371/journal.pone.0220453.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSerotype 3 invasive pneumococcal diseaseHerd protection effectsIPD casesAge groupsPCV13-type invasive pneumococcal diseaseAdult invasive pneumococcal diseaseAdult pneumococcal vaccinationPneumococcal vaccination programAdults 60 yearsVaccine serotypes 4Years of ageAdult age groupsIndirect protection effectPneumococcal vaccinationPneumococcal diseasePolysaccharide vaccineVaccine recommendationsChildhood vaccinationVaccination programVaccine formulationsAdult coverageAdults 60Protection effectSerotype 4